TOKYO, Jan 18, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society […]
TOKYO and CAMBRIDGE, Mass., Jan 9, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that under the Accelerated Approval Pathway the U.S. Food […]
TOKYO, Nov 24, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data […]
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification from Japan’s Ministry of Health, Labour, and Welfare (MHLW) that […]
SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin […]
HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of […]
LAUSANNE, Switzerland, Sep 6, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough […]
TOKYO, Sep 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline […]
TOKYO and RAHWAY, N.J., Aug 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and […]
Seoul, Korea,June8, 2022- (SEAPRWire) – Lemon Healthcare, a customized service platform, is using blockchain technology to improve the smart healthcare ecosystem for patients. The company is on a mission to create […]
SHANGHAI, CHINA, Jun 7, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class […]
TOKYO, Jun 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 […]
TOKYO, May 27, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the […]
TOKYO, Mar 28, 2022 – (JCN Newswire via SEAPRWire.com) – Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication […]
Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, […]
HONG KONG, Mar 14, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based […]
TOKYO, Mar 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, […]
